Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 1237 (MIR1237)
- Target
- MIR1237
- Molecular classification
- microRNA (miRNA), Non-coding RNA
01
Overview
MicroRNA 1237 is a short (20-24 nucleotide) non-coding RNA molecule that regulates gene expression at the post-transcriptional level by guiding the RNA-induced silencing complex (RISC) to target mRNAs, resulting in their translational inhibition or degradation. It has context-dependent disease associations, notably acting as a tumor marker in oral squamous cell carcinoma with upregulation linked to poor prognosis and recurrence, and as a tumor suppressor in gastric cancer where it is epigenetically silenced via DNA methylation. MIR1237 is predicted or validated to regulate genes critical for cancer progression, including ERBB3 and CCND2, impacting cell proliferation, migration, and invasion. Its expression pattern and epigenetic status are being explored for cancer diagnosis, prognosis, and potential future therapeutic targeting.
- Other names
- hsa-mir-1237MIRN1237MIR1237
02
Mechanism of action
Post-transcriptional gene silencing via imperfect base pairing with target mRNAs; Indirect modulation of cellular pathways (e.g., PI3K-AKT signaling, transcriptional misregulation in cancer); Downregulation of specific cancer-related genes (e.g., ERBB3, CCND2)
03
Biological functions
Post-transcriptional regulation of gene expressionRegulation of stability and translation of mRNAsModulation of cell proliferation, migration, and invasion (inhibition in cancer contexts)
04
Disease associations
Cancer (reported in oral squamous cell carcinoma, gastric cancer, colorectal cancer, acute lymphoblastic leukemia)Tumorigenesis and tumor progression (as an onco-miR or tumor suppressor depending on context)Disease prognosis (e.g., poor prognosis signature in oral cancer, tumor recurrence prediction)
05
Safety considerations
Lack of established safety profile for direct targeting; general concerns include off-target effects and delivery specificity for miRNA-based therapiesPotential risks exist with miRNA modulating therapies due to broad gene regulatory networks
06
Biomarkers
Overexpression in oral squamous cell carcinoma (OSCC), especially in early-stage and low tumor depth, associated with tumor recurrence and poor prognosisMethylation status in gastric cancer as a marker for epigenetic silencing
Beyond the preview
Go deeper on MicroRNA 1237 (MIR1237).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MicroRNA 1237 (MIR1237).